Phaseline

Companies › PhenoNet

PhenoNet: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cromolyn Sodium
Mast cell stabilizer
–Phase 2Amyotrophic Lateral Sclerosis (ALS)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07142291Cromolyn SodiumPhase 2Amyotrophic Lateral Sclerosis (ALS)NeurologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals Glycomine RyCarma Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.